A recommended scale for cognitive screening in clinical trials of Parkinson's disease
Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make re...
Gespeichert in:
| Veröffentlicht in: | Movement disorders 2010-11, Vol.25 (15), p.2501-2507 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2507 |
|---|---|
| container_issue | 15 |
| container_start_page | 2501 |
| container_title | Movement disorders |
| container_volume | 25 |
| creator | Chou, Kelvin L. Amick, Melissa M. Brandt, Jason Camicioli, Richard Frei, Karen Gitelman, Darren Goldman, Jennifer Growdon, John Hurtig, Howard I. Levin, Bonnie Litvan, Irene Marsh, Laura Simuni, Tanya Tröster, Alexander I. Uc, Ergun Y. |
| description | Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time ( |
| doi_str_mv | 10.1002/mds.23362 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2978783</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1859468274</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6092-388bb93a810c6b05c2b4abded5d6925f627ff1aa5ff602764584f8abdc301fd43</originalsourceid><addsrcrecordid>eNp90V1vFCEUBuCJ0di1euEfMCTGtF5My4HhY25MmlqrSdUmttY7wjCwUmegwmy1_17W3a4fiV6RwMPhcN6qegx4DzAm-2Of9wilnNypZsAo1JIwcbeaYSlZTUGyrepBzpcYAzDg96stgqWQbQuz6vwAJWviONrQ2x5loweLXEzIxHnwk7-2ZS9ZG3yYIx-QGXzwBaEpeT1kFB061emLDzmGnYx6n63O9mF1z5VT-2i9blfnr47ODl_XJ--P3xwenNSG45bUVMqua6mWgA3vMDOka3RX-mA9bwlznAjnQGvmHMdE8IbJxskiDMXg-oZuVy9Wda8W3Wh7Y8OU9KCukh91ulFRe_XnSfCf1TxeK9KKMgFaCuysC6T4dWHzpEafjR0GHWxcZCWBAJFMLOXuf2WZcttwScSyq6d_0cu4SKEMQgERhAqKG1bU85UyKeacrNu0DVgtY1UlVvUz1mKf_P7PjbzNsYBna6CXEbqkg_H5l6MNAAhR3P7KffODvfn3i-rtyw-3T9erGz5P9vvmRslccUEFUxfvjtXpRXP2kX6SStAfevbImg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1272373045</pqid></control><display><type>article</type><title>A recommended scale for cognitive screening in clinical trials of Parkinson's disease</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Chou, Kelvin L. ; Amick, Melissa M. ; Brandt, Jason ; Camicioli, Richard ; Frei, Karen ; Gitelman, Darren ; Goldman, Jennifer ; Growdon, John ; Hurtig, Howard I. ; Levin, Bonnie ; Litvan, Irene ; Marsh, Laura ; Simuni, Tanya ; Tröster, Alexander I. ; Uc, Ergun Y.</creator><creatorcontrib>Chou, Kelvin L. ; Amick, Melissa M. ; Brandt, Jason ; Camicioli, Richard ; Frei, Karen ; Gitelman, Darren ; Goldman, Jennifer ; Growdon, John ; Hurtig, Howard I. ; Levin, Bonnie ; Litvan, Irene ; Marsh, Laura ; Simuni, Tanya ; Tröster, Alexander I. ; Uc, Ergun Y. ; Parkinson Study Group Cognitive/Psychiatric Working Group ; on behalf of the Parkinson Study Group Cognitive/Psychiatric Working Group</creatorcontrib><description>Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD. © 2010 Movement Disorder Society</description><identifier>ISSN: 0885-3185</identifier><identifier>EISSN: 1531-8257</identifier><identifier>DOI: 10.1002/mds.23362</identifier><identifier>PMID: 20878991</identifier><identifier>CODEN: MOVDEA</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Biological and medical sciences ; Clinical Trials as Topic ; Cognition ; Cognition Disorders - complications ; Cognition Disorders - diagnosis ; Cognition Disorders - psychology ; cognitive impairment ; cognitive screening ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Humans ; Medical sciences ; Movement disorders ; Neurology ; Neuropsychological Tests ; Parkinson Disease - complications ; Parkinson Disease - psychology ; Parkinson's disease ; Psychometrics ; Surveys and Questionnaires</subject><ispartof>Movement disorders, 2010-11, Vol.25 (15), p.2501-2507</ispartof><rights>Copyright © 2010 Movement Disorder Society</rights><rights>2015 INIST-CNRS</rights><rights>2010 Movement Disorder Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6092-388bb93a810c6b05c2b4abded5d6925f627ff1aa5ff602764584f8abdc301fd43</citedby><cites>FETCH-LOGICAL-c6092-388bb93a810c6b05c2b4abded5d6925f627ff1aa5ff602764584f8abdc301fd43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmds.23362$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmds.23362$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23411177$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20878991$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chou, Kelvin L.</creatorcontrib><creatorcontrib>Amick, Melissa M.</creatorcontrib><creatorcontrib>Brandt, Jason</creatorcontrib><creatorcontrib>Camicioli, Richard</creatorcontrib><creatorcontrib>Frei, Karen</creatorcontrib><creatorcontrib>Gitelman, Darren</creatorcontrib><creatorcontrib>Goldman, Jennifer</creatorcontrib><creatorcontrib>Growdon, John</creatorcontrib><creatorcontrib>Hurtig, Howard I.</creatorcontrib><creatorcontrib>Levin, Bonnie</creatorcontrib><creatorcontrib>Litvan, Irene</creatorcontrib><creatorcontrib>Marsh, Laura</creatorcontrib><creatorcontrib>Simuni, Tanya</creatorcontrib><creatorcontrib>Tröster, Alexander I.</creatorcontrib><creatorcontrib>Uc, Ergun Y.</creatorcontrib><creatorcontrib>Parkinson Study Group Cognitive/Psychiatric Working Group</creatorcontrib><creatorcontrib>on behalf of the Parkinson Study Group Cognitive/Psychiatric Working Group</creatorcontrib><title>A recommended scale for cognitive screening in clinical trials of Parkinson's disease</title><title>Movement disorders</title><addtitle>Mov. Disord</addtitle><description>Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD. © 2010 Movement Disorder Society</description><subject>Biological and medical sciences</subject><subject>Clinical Trials as Topic</subject><subject>Cognition</subject><subject>Cognition Disorders - complications</subject><subject>Cognition Disorders - diagnosis</subject><subject>Cognition Disorders - psychology</subject><subject>cognitive impairment</subject><subject>cognitive screening</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Movement disorders</subject><subject>Neurology</subject><subject>Neuropsychological Tests</subject><subject>Parkinson Disease - complications</subject><subject>Parkinson Disease - psychology</subject><subject>Parkinson's disease</subject><subject>Psychometrics</subject><subject>Surveys and Questionnaires</subject><issn>0885-3185</issn><issn>1531-8257</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90V1vFCEUBuCJ0di1euEfMCTGtF5My4HhY25MmlqrSdUmttY7wjCwUmegwmy1_17W3a4fiV6RwMPhcN6qegx4DzAm-2Of9wilnNypZsAo1JIwcbeaYSlZTUGyrepBzpcYAzDg96stgqWQbQuz6vwAJWviONrQ2x5loweLXEzIxHnwk7-2ZS9ZG3yYIx-QGXzwBaEpeT1kFB061emLDzmGnYx6n63O9mF1z5VT-2i9blfnr47ODl_XJ--P3xwenNSG45bUVMqua6mWgA3vMDOka3RX-mA9bwlznAjnQGvmHMdE8IbJxskiDMXg-oZuVy9Wda8W3Wh7Y8OU9KCukh91ulFRe_XnSfCf1TxeK9KKMgFaCuysC6T4dWHzpEafjR0GHWxcZCWBAJFMLOXuf2WZcttwScSyq6d_0cu4SKEMQgERhAqKG1bU85UyKeacrNu0DVgtY1UlVvUz1mKf_P7PjbzNsYBna6CXEbqkg_H5l6MNAAhR3P7KffODvfn3i-rtyw-3T9erGz5P9vvmRslccUEFUxfvjtXpRXP2kX6SStAfevbImg</recordid><startdate>20101115</startdate><enddate>20101115</enddate><creator>Chou, Kelvin L.</creator><creator>Amick, Melissa M.</creator><creator>Brandt, Jason</creator><creator>Camicioli, Richard</creator><creator>Frei, Karen</creator><creator>Gitelman, Darren</creator><creator>Goldman, Jennifer</creator><creator>Growdon, John</creator><creator>Hurtig, Howard I.</creator><creator>Levin, Bonnie</creator><creator>Litvan, Irene</creator><creator>Marsh, Laura</creator><creator>Simuni, Tanya</creator><creator>Tröster, Alexander I.</creator><creator>Uc, Ergun Y.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20101115</creationdate><title>A recommended scale for cognitive screening in clinical trials of Parkinson's disease</title><author>Chou, Kelvin L. ; Amick, Melissa M. ; Brandt, Jason ; Camicioli, Richard ; Frei, Karen ; Gitelman, Darren ; Goldman, Jennifer ; Growdon, John ; Hurtig, Howard I. ; Levin, Bonnie ; Litvan, Irene ; Marsh, Laura ; Simuni, Tanya ; Tröster, Alexander I. ; Uc, Ergun Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6092-388bb93a810c6b05c2b4abded5d6925f627ff1aa5ff602764584f8abdc301fd43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Biological and medical sciences</topic><topic>Clinical Trials as Topic</topic><topic>Cognition</topic><topic>Cognition Disorders - complications</topic><topic>Cognition Disorders - diagnosis</topic><topic>Cognition Disorders - psychology</topic><topic>cognitive impairment</topic><topic>cognitive screening</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Movement disorders</topic><topic>Neurology</topic><topic>Neuropsychological Tests</topic><topic>Parkinson Disease - complications</topic><topic>Parkinson Disease - psychology</topic><topic>Parkinson's disease</topic><topic>Psychometrics</topic><topic>Surveys and Questionnaires</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chou, Kelvin L.</creatorcontrib><creatorcontrib>Amick, Melissa M.</creatorcontrib><creatorcontrib>Brandt, Jason</creatorcontrib><creatorcontrib>Camicioli, Richard</creatorcontrib><creatorcontrib>Frei, Karen</creatorcontrib><creatorcontrib>Gitelman, Darren</creatorcontrib><creatorcontrib>Goldman, Jennifer</creatorcontrib><creatorcontrib>Growdon, John</creatorcontrib><creatorcontrib>Hurtig, Howard I.</creatorcontrib><creatorcontrib>Levin, Bonnie</creatorcontrib><creatorcontrib>Litvan, Irene</creatorcontrib><creatorcontrib>Marsh, Laura</creatorcontrib><creatorcontrib>Simuni, Tanya</creatorcontrib><creatorcontrib>Tröster, Alexander I.</creatorcontrib><creatorcontrib>Uc, Ergun Y.</creatorcontrib><creatorcontrib>Parkinson Study Group Cognitive/Psychiatric Working Group</creatorcontrib><creatorcontrib>on behalf of the Parkinson Study Group Cognitive/Psychiatric Working Group</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Movement disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chou, Kelvin L.</au><au>Amick, Melissa M.</au><au>Brandt, Jason</au><au>Camicioli, Richard</au><au>Frei, Karen</au><au>Gitelman, Darren</au><au>Goldman, Jennifer</au><au>Growdon, John</au><au>Hurtig, Howard I.</au><au>Levin, Bonnie</au><au>Litvan, Irene</au><au>Marsh, Laura</au><au>Simuni, Tanya</au><au>Tröster, Alexander I.</au><au>Uc, Ergun Y.</au><aucorp>Parkinson Study Group Cognitive/Psychiatric Working Group</aucorp><aucorp>on behalf of the Parkinson Study Group Cognitive/Psychiatric Working Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A recommended scale for cognitive screening in clinical trials of Parkinson's disease</atitle><jtitle>Movement disorders</jtitle><addtitle>Mov. Disord</addtitle><date>2010-11-15</date><risdate>2010</risdate><volume>25</volume><issue>15</issue><spage>2501</spage><epage>2507</epage><pages>2501-2507</pages><issn>0885-3185</issn><eissn>1531-8257</eissn><coden>MOVDEA</coden><abstract>Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD. © 2010 Movement Disorder Society</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>20878991</pmid><doi>10.1002/mds.23362</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-3185 |
| ispartof | Movement disorders, 2010-11, Vol.25 (15), p.2501-2507 |
| issn | 0885-3185 1531-8257 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2978783 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Biological and medical sciences Clinical Trials as Topic Cognition Cognition Disorders - complications Cognition Disorders - diagnosis Cognition Disorders - psychology cognitive impairment cognitive screening Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Humans Medical sciences Movement disorders Neurology Neuropsychological Tests Parkinson Disease - complications Parkinson Disease - psychology Parkinson's disease Psychometrics Surveys and Questionnaires |
| title | A recommended scale for cognitive screening in clinical trials of Parkinson's disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T12%3A19%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20recommended%20scale%20for%20cognitive%20screening%20in%20clinical%20trials%20of%20Parkinson's%20disease&rft.jtitle=Movement%20disorders&rft.au=Chou,%20Kelvin%20L.&rft.aucorp=Parkinson%20Study%20Group%20Cognitive/Psychiatric%20Working%20Group&rft.date=2010-11-15&rft.volume=25&rft.issue=15&rft.spage=2501&rft.epage=2507&rft.pages=2501-2507&rft.issn=0885-3185&rft.eissn=1531-8257&rft.coden=MOVDEA&rft_id=info:doi/10.1002/mds.23362&rft_dat=%3Cproquest_pubme%3E1859468274%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1272373045&rft_id=info:pmid/20878991&rfr_iscdi=true |